Do You Really Lose Muscle on Semaglutide or Tirzepatide?
TakeawaysThe podcast features Dr. Grant Tinsley, a body composition expert.The discussion revolves around a case series on body composition effects.GLP-1 receptor agonists are a focus of the research.The importance of resistance training in weight loss is emphasized.Patient case studies provide insights into individual experiences.The first patient lost a significant amount of fat mass while preserving lean mass.The second patient achieved remarkable body composition changes in a short time.The third patient showed positive changes over a longer duration.The need for more randomized trials is highlighted.The conversation underscores the role of exercise and nutrition in weight management.Tap or Click here to see more from Dr. GrantTap here for scientific references in this episode.
-------- Â
33:50
--------
33:50
Predatory Lab Testing: What They’re Not Telling You
TakeawaysDirect-to-consumer lab testing is on the rise, with significant marketing efforts behind it.Many patients feel brushed off by traditional healthcare providers, leading them to seek alternative testing options.Communication between patients and healthcare providers is often inadequate, contributing to misunderstandings about health.Over-testing can lead to unnecessary anxiety and misinterpretation of results.Fitness influencers often promote lab testing without proper medical training, which can be harmful.There is a need for ethical practices in lab testing and patient care.Patients should be cautious of companies that upsell supplements based on lab results.The healthcare system often fails to provide adequate time for patient concerns to be addressed.Understanding lab results requires skilled interpretation, which is often lacking in direct-to-consumer models.A collaborative approach among healthcare professionals is necessary to improve patient outcomes.Click to join Dr. Spencer's online clinic if you need help with this  Click here to check out Barbell Medicine
-------- Â
49:50
--------
49:50
CVS Pulled the Plug on Zepbound?!
In this episode of the Dr. Lift podcast, hosts Dr. Spencer Nadolsky and Dr. Karl discuss the recent changes in obesity medication coverage, particularly focusing on the CVS Caremark decision to drop ZEPBound from their formulary in favor of Wegovi. They explore the implications of this decision for patients and providers, the role of pharmacy benefit managers (PBMs) in healthcare, and the ongoing advocacy efforts to ensure access to effective obesity treatments. The conversation highlights the complexities of insurance coverage, the need for patient-centered care, and the importance of making medications more affordable.- The recent changes in obesity medication coverage have raised concerns among providers and patients.- CVS Caremark's decision to drop ZEPBound has sparked a petition advocating for better access to medications.- Pharmacy Benefit Managers (PBMs) play a significant role in determining medication coverage and costs.- There is a need for more nuanced insurance policies that consider patient needs and clinical severity.- Advocacy efforts are crucial in reversing negative trends in medication coverage.- Patients often face challenges with prior authorization processes when switching medications.- The cost of obesity medications is a significant barrier to access for many patients.- Insurance companies are increasingly dropping coverage for anti-obesity medications, impacting patient care.- The conversation emphasizes the importance of patient-centered care in obesity treatment.- There is a call for making obesity medications more affordable and accessible to patients.https://www.change.org/p/stop-cvs-caremark-s-zepbound-ban-restore-coverage-of-the-superior-obesity-medicationClick to join Dr. Spencer's online clinic if you need help with thisÂ
-------- Â
20:12
--------
20:12
More Than Weight Loss? GLP-1s and Cardiovascular Risk
In this episode of the Dr. Lift podcast, hosts Dr. Spencer Nadolsky and Dr. Karl discuss the Surpass CVOT trial, which evaluates the cardiovascular outcomes of Monjaro compared to Dulaglutide (Trulicity). They delve into the significance of the trial, the implications of the results, and the potential benefits of Monjaro for patients with type 2 diabetes and cardiovascular risks. The conversation highlights the importance of understanding cardiovascular outcome trials and the evolving landscape of diabetes medications.Takeaways: The Surpass CVOT trial compares Mounjaro to Dulaglutide.Dulaglutide has shown cardiovascular benefits in previous trials.The trial results indicate Monjaro is at least not inferior to Dulaglutide.There is a trend towards better cardiovascular outcomes with Mounjaro.Weight loss and glycemic control are significant benefits of Mounjaro.The trial did not include a placebo, but used a putative analysis.The results are reassuring for patients at high cardiovascular risk.The conversation emphasizes the importance of comprehensive treatment for metabolic diseases.The hosts express enthusiasm for the potential of Mounjaro.Future discussions will delve deeper into the trial's findings.     Â
-------- Â
11:16
--------
11:16
Semaglutide vs. Tirzepatide: Are We Closing the Gap?
How the STEP-UP trial came to life,  and what made the 7.2mg dose possibleWhat the data actually says about weight loss and side effects at higher dosesWhy trial design, pharmacokinetics, and estimands matter more than you thinkWhat’s coming next in obesity meds: duals, triples, and even antagonistsThe real talk on intermittent fasting, access issues, and preaching vs. scienceSign up for Dr. Spencer''s Clinic
Drs. Spencer and Karl Nadolsky talk about nutrition, medicine, and fitness through the lens of two physicians who lift weights. Both doctors are former NCAA division 1 wrestlers who have gone into medicine. Dr. Spencer Nadolsky is a board certified family physician specialized in obesity medicine and lipidology. Dr. Karl Nadolsky is a board certified endocrinologist also specialized in obesity medicine.
New Zealand